EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

Jacob A Boyer iD, Ezra Y Rosen, Malvika Sharma iD, Madeline A Dorso iD, Nicholas Mai iD, Corina Amor, Jason M Reiter, Ram Kannan, Sunyana Gadal iD, Jianing Xu, Matthew Miele, Zhuoning Li und 15 weitere

Proceedings of the National Academy of Sciences · 29.07.2025 · 122 (30)

DOI: 10.1073/pnas.2424286122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 21.07.2025. Verfasst von Jacob A Boyer und 26 weiteren Autor:innen. Beteiligte Einrichtung: Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Eukaryotic Initiation Factor-4A, Protein Biosynthesis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Cancer Institute (NCI), NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most breast cancers depend on hormone-stimulated estrogen receptor alpha (ER) activity and are sensitive to ER inhibition. Resistance can arise from activating mutations in the gene encoding ER ( ESR1 ) or from reactivation of downstream targets. Newer ER antagonists occasionally show efficacy but are largely ineffective as single agents in the long term. Here, we show that ER translation is eIF4E/cap-independent yet sensitive to inhibitors of the translation initiation factor eIF4A. EIF4A inhibition reduces the expression of ER and cell cycle regulators such as cyclin D1. This leads to growth suppression in ligand-independent breast cancer models, including those driven by ER mutants and fusion proteins. Efficacy is enhanced by adding the ER degrader, fulvestrant. The combination further lowers ER expression and blocks tumor growth in vitro and in vivo. In an early clinical trial (NCT04092673), the eIF4A inhibitor zotatifin was combined with either fulvestrant or fulvestrant plus CDK4 inhibitor, abemaciclib, in patients with acquired resistance to these agents. Multiple clinical responses including a handful of durable regressions were observed, with little toxicity. Thus, eIF4A inhibition could be useful for treating ER+ breast cancer resistant to other modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEstrogen Receptor alphaEukaryotic Initiation Factor-4AProtein BiosynthesisHumansFemaleFulvestrantAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticMCF-7 Cells

Stichwörter der Autor:innen

breast cancereIF4Aestrogen receptortranslationzotatifin

Substanzen

Estrogen Receptor alphaFulvestrantEukaryotic Initiation Factor-4AESR1 protein, human

Autor:innen und Institutionen

  • Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Program in Molecular Pharmacology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Ludwig Institute for Cancer Research, Princeton Branch, Princeton, NJ 08544.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

ORCID-Profile: Jacob A Boyer, Malvika Sharma, Madeline A Dorso, Nicholas Mai, Sunyana Gadal, Qing Chang, Stephan Worland, Gary G Chiang, Peggy A Thompson, Guangli Yang, Ouathek Ouerfelli, Elisa de Stanchina, Sarat Chandarlapaty, Neal Rosen

Förderung

  • HHS | NIH | National Cancer Institute (NCI)
  • NCI NIH HHS

Zitieren

APA

Boyer, J. A., Rosen, E. Y., Sharma, M., Dorso, M. A., Mai, N., Amor, C., Reiter, J. M., Kannan, R., Gadal, S., Xu, J., Miele, M., Li, Z., Chen, X., Chang, Q., Pareja, F., Worland, S., Warner, D., Sperry, S., Chiang, G. G., …, & Rosen, N. (2025). eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer. Proceedings of the National Academy of Sciences, 122(30). https://doi.org/10.1073/pnas.2424286122

Vancouver

Boyer JA, Rosen EY, Sharma M, Dorso MA, Mai N, Amor C, et al. eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer. Proceedings of the National Academy of Sciences. 2025;122(30). doi:10.1073/pnas.2424286122

BibTeX
@article{Boyer2025,
  author = {Boyer, Jacob A and Rosen, Ezra Y and Sharma, Malvika and Dorso, Madeline A and Mai, Nicholas and Amor, Corina and Reiter, Jason M and Kannan, Ram and Gadal, Sunyana and Xu, Jianing and Miele, Matthew and Li, Zhuoning and Chen, Xiaoping and Chang, Qing and Pareja, Fresia and Worland, Stephan and Warner, Douglas and Sperry, Sam and Chiang, Gary G and Thompson, Peggy A and Yang, Guangli and Ouerfelli, Ouathek and Drilon, Alexander and de Stanchina, Elisa and Wendel, Hans-Guido and Chandarlapaty, Sarat and Rosen, Neal},
  title = {eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {30},
  doi = {10.1073/pnas.2424286122}
}
Kostenlos starten →